Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: | NSE:

Fundamental Analysis of Vaishali Pharma Ltd

About the Company - Vaishali Pharma Ltd

Vaishali Pharma Ltd. is a Public Limited Listed company incorporated on 25/03/2008 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L52310MH2008PLC181632 and registration number is 181632. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 75.82 Cr. and Equity Capital is Rs. 10.55 Cr. for the Year ended 31/03/2022.
Pharmaceuticals706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra
NamePosition Held
Mr. Atul VasaniChairman & Managing Director
Mr. Dewansh VasaniExecutive Director
Mrs. Jagruti VasaniWhole Time Director
Mr. Ashvin GanatraIndependent Director
Mr. Manish VedIndependent Director
Mr. Pratik JakheliaIndependent Director

Vaishali Pharma Ltd. Share Price Update

Share PriceValue
Previous Day₹154.75

Basic Stock Data of Vaishali Pharma Ltd

Market Cap 168 Cr.
Current Price 159
High / Low204/115
Stock P/E28.8
Book Value 41.8
Dividend Yield0.00 %
ROCE21.7 %
ROE19.7 %
Face Value 10.0

Data Source:

Competitors of Vaishali Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Vivimed Labs Ltd 41.0 Cr. 4.957.76/4.85 21.30.00 %51.5 %163 % 2.00
Venus Remedies Ltd 456 Cr. 341430/15115.7 3520.00 %7.75 %5.90 % 10.0
Unichem Laboratories Ltd 3,645 Cr. 518580/272 3420.00 %4.58 %7.05 % 2.00
Natco Pharma Ltd 18,407 Cr. 1,0281,108/52014.4 2960.92 %17.7 %15.3 % 2.00
Wanbury Ltd 549 Cr. 168168/33.022.9 6.800.00 %16.9 %% 10.0
Industry Average4,619.60 Cr411.9910.60203.620.18%19.69%38.25%5.20

Vaishali Pharma Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Operating Profit2.70-1.351.262.222.490.882.202.593.560.782.312.652.95
OPM %12.68%-7.15%15.24%11.18%11.18%3.46%21.61%19.68%17.72%2.97%17.21%21.08%10.57%
Other Income0.320.570.570.360.310.550.430.740.530.530.360.300.47
Profit before tax2.32-1.961.081.872.150.632.012.663.550.622.122.362.87
Tax %25.86%26.53%25.00%25.13%25.12%68.25%24.88%24.81%25.07%29.03%25.00%27.97%26.13%
Net Profit1.72-1.450.811.401.610.201.511.992.660.441.591.702.11
EPS in Rs1.63-1.370.771.331.530.191.431.892.520.421.501.601.99

Vaishali Pharma Ltd Quarterly Chart

Vaishali Pharma Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit0.601.572.48-0.290.553.482.792.080.912.656.889.388.69
OPM %0.74%1.32%2.05%-0.31%0.82%5.44%4.12%2.77%1.51%4.93%9.07%13.47%10.84%
Other Income-
Profit before tax0.600.890.620.15-
Tax %36.67%32.58%50.00%-6.67%-300.00%32.04%40.74%37.17%62.50%25.71%29.72%25.31%
Net Profit0.380.600.300.16-0.030.710.800.710.
EPS in Rs19.007.503.752.00-0.381.480.760.680.031.003.816.265.51
Dividend Payout %-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%

Vaishali Pharma Ltd Profit & Loss Yearly Chart

YoY Net Profit Growth
YoY Net Profit Growth (%)57.89%-50.00%-46.67%-118.75%2466.67%12.68%-11.25%-95.77%3400.00%282.86%64.18%
Change in YoY Net Profit Growth (%)0.00%-107.89%3.33%-72.08%2585.42%-2453.99%-23.93%-84.52%3495.77%-3117.14%-218.68%

Vaishali Pharma Ltd Growth

Compounded Sales Growth
10 Years:-5%
5 Years:1%
3 Years:5%
Compounded Profit Growth
10 Years:27%
5 Years:53%
3 Years:504%
Stock Price CAGR
10 Years:%
5 Years:40%
3 Years:61%
1 Year:-5%
Return on Equity
10 Years:10%
5 Years:10%
3 Years:15%
Last Year:20%

Vaishali Pharma Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital0.100.500.500.500.503.006.596.5910.5510.5510.5510.5510.60
Other Liabilities20.1036.2131.5917.4725.1718.0425.2230.2827.7745.8534.4523.6320.85
Total Liabilities34.5748.5853.4345.8049.4144.8764.2268.7566.2086.1281.6278.9080.17
Fixed Assets0.
Other Assets34.3748.4052.6543.7447.6343.2062.4566.9464.2084.4279.5275.8277.26
Total Assets34.5748.5853.4345.8049.4144.8764.2268.7566.2086.1281.6278.9080.17

Vaishali Pharma Ltd Reserves and Borrowings Chart

Vaishali Pharma Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 0.003.80-7.04-3.724.590.46-9.464.313.222.011.321.08
Cash from Investing Activity 0.000.14-0.241.783.070.691.06-0.28-0.02-0.11-0.850.28
Cash from Financing Activity 0.00-3.606.491.93-7.62-1.208.50-3.99-3.14-1.810.42-1.73
Net Cash Flow0.000.33-0.790.000.04-

Vaishali Pharma Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days106.68115.64115.51132.63221.16213.80240.14240.22285.67452.97281.67280.90
Inventory Days17.1726.0413.2819.777.4811.395.216.294.673.6220.36
Days Payable115.3398.9965.64144.6399.98136.37130.38168.82320.63163.13120.15
Cash Conversion Cycle106.6817.4742.5680.2796.29121.29115.16115.05123.14137.01122.16181.11
Working Capital Days54.2129.7458.5497.81109.10114.97177.17153.70195.77238.60196.41252.82
ROCE %3.95%13.64%19.29%14.03%12.78%16.17%12.76%9.78%6.87%10.24%18.78%21.69%

Vaishali Pharma Ltd Financial Efficiency Indicators Chart

Vaishali Pharma Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders6,55810,30610,82210,2119,6119,3908,3478,9549,3769,5739,9839,181

Vaishali Pharma Ltd Shareholding Pattern Chart

No. of Vaishali Pharma Ltd Shareholders

This stock is not held by any mutual fund

Vaishali Pharma Ltd ROCE Trend

Vaishali Pharma Ltd EPS Trend

Vaishali Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)6.263.820.990.031.08
Diluted EPS (Rs.)5.913.820.990.031.08
Cash EPS (Rs.)6.744.251.400.441.49
Book Value[Excl.RevalReserv]/Share (Rs.)31.2624.9921.2620.2732.47
Book Value[Incl.RevalReserv]/Share (Rs.)31.2624.9921.2620.2732.47
Revenue From Operations / Share (Rs.)66.0571.8950.9956.97113.92
PBDIT / Share (Rs.)10.778.204.212.846.13
PBIT / Share (Rs.)10.297.763.812.435.72
PBT / Share (Rs.)8.395.431.330.071.72
Net Profit / Share (Rs.)6.263.810.990.031.08
PBDIT Margin (%)16.3011.398.264.995.38
PBIT Margin (%)15.5810.797.464.265.02
PBT Margin (%)12.697.552.610.131.50
Net Profit Margin (%)9.475.301.940.050.95
Return on Networth / Equity (%)20.0215.264.660.153.33
Return on Capital Employeed (%)23.1727.5714.949.9214.35
Return On Assets (%)8.364.921.210.041.03
Long Term Debt / Equity (X)
Total Debt / Equity (X)0.410.780.710.750.75
Asset Turnover Ratio (%)0.860.900.700.891.13
Current Ratio (X)2.271.471.371.521.48
Quick Ratio (X)2.171.461.361.501.46
Interest Coverage Ratio (X)5.663.521.701.211.53
Interest Coverage Ratio (Post Tax) (X)4.292.641.401.011.27
Enterprise Value (Cr.)166.5589.1749.8557.9544.59
EV / Net Operating Revenue (X)2.391.180.920.960.59
EV / EBITDA (X)14.6610.3211.2219.3211.04
MarketCap / Net Operating Revenue (X)2.210.920.630.700.38
Price / BV (X)4.672.651.531.981.34
Price / Net Operating Revenue (X)2.210.920.630.700.38

Vaishali Pharma Ltd Profitability Ratios (%)

Vaishali Pharma Ltd Liquidity Ratios

Vaishali Pharma Ltd Liquidity Ratios (%)

Vaishali Pharma Ltd Interest Coverage Ratios (X)

Vaishali Pharma Ltd Valuation Ratios

Fair Value / Intrinsic Value of Vaishali Pharma Ltd

Fair Value: ₹241.90

The stock is undervalued by 52.14% compared to the current price ₹159

*Investments are subject to market risks

Strength and Weakness of Vaishali Pharma Ltd

  1. The company has shown consistent growth in sales (79.13 cr) and profit (2.29 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 6.00 and average Dividend Yield of 4.90%.
  2. The stock has a low average ROCE of 13.33%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 139.90, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 104.85, which may not be favorable.
  5. The company has higher borrowings (17.77) compared to reserves (11.07), which may suggest financial risk.

Should I Buy Vaishali Pharma Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Vaishali Pharma Ltd:
    1. Net Profit Margin: 9.47%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 23.17% (Industry Average ROCE: 19.69%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 4.29
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 2.17
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✗ Stock P/E: 28.8 (Industry average Stock P/E: 10.6)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.41
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vaishali Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE